Clinical trials: Covid19 Vaccine
Covid19 Vaccine
Covid-19 Vaccine Response in Elderly Subjects
The objective of this research is to assess the amplitude and quality of the vaccine response against SARS-CoV-2, defined here by its characteristics established at 3 months, and its persistence over time, defined here at 9…
- Trial name
- MONITOCOVAGING (NCT04760704)
- Testing
- Specific antibody and cellular immune response after anti-SARS-CoV-2 vaccine administration
- Where
- France
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
COVID-19
Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 Vaccine
This is an open-label, randomized, parallel-controlled clinical trial to evaluate the safety and immunogenicity of heterologous prime-boost immunization with an aerosolized (Ad5-nCoV-IH) or intramuscular (Ad5-nCoV-IM) Ad5-nCoV…
- Trial name
- NCT05303584
- Testing
- Ad5-nCoV-IH, Ad5-nCoV-IM, CoronaVac
- Where
- China
- Volunteers
- 362 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
COVID-19 Vaccine
Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC
The objective is to determine the safety and immunogenicity of two different strengths (3 µg and 6 µg) of an inactivated COVID 19 Vaccine compared to placebo so that to demonstrate the safety and efficacy in prophylaxis of…
- Trial name
- ERUCOV-VAC (NCT04691947)
- Testing
- ERUCOV-VAC
- Where
- Turkey (Türkiye)
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Health Institutes of Turkey
COVID-19
Homologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine
Open-label, prospective intervention study of IndoVac® as a single, homologous booster dose
- Trial name
- NCT05933278
- Testing
- SARS-CoV-2 Subunit Recombinant Protein Vaccine
- Where
- Indonesia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
COVID-19
The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated Adults
SCTV01C-02-1 is a randomized, double-blind, placebo controlled Phase Ⅰ/Ⅱ clinical trial of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant bivalent trimeric S protein vaccine manufactured by…
- Trial name
- NCT05148091
- Testing
- SCTV01C, Adjuvant, Saline
- Where
- 5 sites in China
- Volunteers
- 478 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID -19, SARS CoV 2 Infection
Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that emerged in the human population in Wuhan City, Hubei Province, China in December 2019.
- Trial name
- NCT07408297
- Testing
- Janssen Ad26COVS1, Pfizer-BioNTech vaccine COVID-19 vaccine, Inactivated Sinopharm or Sinovac COVID-19 vaccine
- Where
- Kenya
- Volunteers
- 1,919 people, healthy volunteers welcome
- Sponsor
- Victoria Biomedical Research Institute
SARS-CoV-2 Infection
A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19)
This is a Phase 2, randomized, observer-blinded study evaluating the safety and immunogenicity of SARS-CoV-2 with Matrix-M™ Adjuvant in people living with human immunodeficiency virus (HIV) (PLWH) and HIV- negative adults…
- Trial name
- COVID-19 (NCT05112848)
- Testing
- NVX-CoV2373
- Where
- 7 sites in South Africa
- Volunteers
- 384 people
- Sponsor
- Novavax
COVID-19, SARS-CoV-2 Infection
The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.
The objective of this study is to evaluate the safety, tolerability, and immunogenicity of SCTV01C in healthy population aged ≥18 years previously vaccinated with inactivated COVID-19 vaccine.
- Trial name
- NCT05043285
- Testing
- SCTV01C
- Where
- United Arab Emirates
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID-19
A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents
This is a multicenter, randomized, and open-label study to evaluate the immune responses and safety profiles of children aged 6-12 years and adolescents aged 13-17 years receiving Ad5-nCoV (intramuscular injection) or Ad5-nCoV-IH…
- Trial name
- NCT05169008
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)
- Where
- 2 sites in Chile
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Psoriasis, Covid19
PsoVac: Educational Needs re Vaccines for Biologic Patients With Psoriasis
To determine if there is a need for further education on vaccines with psoriasis patients who are on a biologic. In regards to the COVID-19, it is important that psoriasis patients - whether on a biologic or not - understand…
- Trial name
- NCT04513847
- Where
- Canada
- Volunteers
- 661 people
- Sponsor
- Dermatrials Research
SARS-CoV-2 Infection, COVID-19
Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age
This study will assess the safety and immunogenicity of a fourth dose (booster) of BNT162b2 when coadministered with SIIV compared to separate administration of the vaccines when given 1 month apart (SIIV followed by BNT162b2)…
- Trial name
- NCT05310084
- Testing
- BNT162b2, Seasonal Inactivated Influenza Vaccine
- Where
- 26 sites in Australia, New Zealand
- Volunteers
- 1,134 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Lung Cancer, Covid19
Anti-SARS-COV2 Vaccination Study in Lung Cancer Patients
Observational and multicenter retrospective study of data collection in hospital centers throughout the Spanish geography. This study aims to be nationwide in order to study general common variables of the patients, as well as…
- Trial name
- VAC-CaP (NCT05009030)
- Testing
- COVID-19 vaccine
- Where
- 51 sites in Spain
- Volunteers
- 794 people
- Sponsor
- Fundación GECP
COVID-19
A Study to Understand is the COVID-19 Vaccine BNT162b2 is Safe in Indonesia People
The purpose of this study is to characterize descriptively the BNT162b2 vaccination safety experience among the Indonesian people.
- Trial name
- NCT05621239
- Testing
- BNT162b2
- Where
- Indonesia
- Volunteers
- 260 people
- Sponsor
- Pfizer
COVID-19 Pandemic
A Phase I/II Clinical Trial in Healthy People Aged 18 Years and Above
This clinical trial is a phase I/II clinical trial to evaluate the safety, immunogenicity and immune persistence of COVID-19 mRNA vaccine in healthy people aged 18 years and above.
- Trial name
- NCT05144139
- Testing
- COVID-19 mRNA vaccine
- Where
- Laos
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Stemirna Therapeutics
COVID-19 Vaccine
Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults
Part I: 12 subjects will receive an open-label 500 µl subcutaneous injection via needle and syringe of the study IMP (CoVac-1). No more than one subject per day will be enrolled.
- Trial name
- pVAC (NCT04546841)
- Testing
- multipeptide cocktail
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Fertility Issues, Vaccine Adverse Reaction
COVID-19 Vaccine and Ovarian Reserve
As Israel is the first country to widely vaccinate its population using the mRNA vaccine against COVID-19, evaluating its influence on ovarian reserve is essential .
- Trial name
- NCT04748172
- Testing
- SARS-CoV-2 virus vaccines, AMH sampling, anti Covid-19 antibody levels (Serology)
- Where
- Israel
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
COVID-19
A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults
The purpose of this trial is to assess the safety and relative efficacy of CVXGA (CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID-19 Vaccine, mRNA; 2024-2025 Formula), a currently approved COVID-19 vaccine in…
- Trial name
- NCT06742281
- Testing
- CVXGA (CVXGA50), COMIRNATY®
- Where
- 55 sites in United States
- Volunteers
- 432 people, healthy volunteers welcome
- Sponsor
- CyanVac LLC
Covid19, SARS-CoV-2 Infection
A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers
This study will test the COVID-19 vaccine candidate AZD1222 to investigate its safety, tolerability and capability of boosting immune responses both in the blood and the lung when administered to the respiratory tract, in…
- Trial name
- COVAXAER01 (NCT05007275)
- Testing
- 1x10^9 vp AZD1222, 5x10^9 vp AZD1222, 1x10^10 vp AZD1222
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Imperial College London
COVID-19
Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 Vaccines
This study is a randomized, simple-blinded comparative phase III clinical trial comparing the immunogenicity of two doses Coronovac to that of a first dose of Coronovac (Sinovac, Beijing, China) followed by a booster shot with…
- Trial name
- NCT05668065
- Testing
- CoronaVac/CoronaVac, CoronaVac/BNT162b2
- Where
- 5 sites in Tunisia
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur de Tunis
Severe Acute Respiratory Infection (SARI), Influenza
Measure of Vaccine Effectiveness to Prevent Hospitalizations for Viral Respiratory Infections in Adults
This study is a prospective, multicentric, observational test negative design study on adults hospitalized for Severe Acute Respiratory Infection (SARI), regardless of their vaccination status.
- Conditions
- Severe Acute Respiratory Infection (SARI), Influenza, COVID-19
- Trial name
- RESPIVAC (NCT05582239)
- Where
- 8 sites in France
- Volunteers
- 2,400 people
- Sponsor
- ANRS, Emerging Infectious Diseases
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.